Latest Content

Dr. Richard Graham from TruTechnologies details the likelihood that Project Trialblazer reduces trial times by 6-to-12 months.

Gerren McHam, vice president of Government and External Affairs, API Innovation Center, explains how geopolitical disruptions like the Strait of Hormuz situation have accelerated the organization's push to develop a national fragility index.

Susan Thomas, chief commercial officer at LucyRx, explains the areas where GLP-1 coverage still lacks.

AI adoption in pharma drops sharply in the domains that matter most for discovery.

Novo's lawsuit claims that Eli Lilly's marketing campaigns for Mounjaro and Zepbound misrepresented the efficacy of Wegovy in comparison.

In today's Pharmaceutical Executive Daily, FDA grants emergency use authorization for Seegene's multiplex PCR assay, a Pfizer medical lead makes the case for continued antiviral use among Covid-19 high-risk patients, and Nuvation Bio's CEO discusses the company's oncology pipeline and philosophy of developing better drugs rather than more of them.

FDA has granted Emergency Use Authorization to Seegene USA's Allplex multiplex PCR assay, making it the first U.S.-authorized test to simultaneously detect and differentiate HSV-1, HSV-2, VZV, and monkeypox virus in a single reaction.

Dr. Gurinder S. Sidhu, senior medical director and U.S. Antiviral Medical Lead, Pfizer, discusses how Covid-19 remains a serious threat to the roughly 75% of American adults who qualify as high-risk, and pushes back against clinician complacency.

Nuvation Bio’s president, CEO, and founder discusses the company’s mission, approach to developing a global strategy, and how it manages its increasing pipeline.

Gerren McHam, vice president of Government and External Affairs, API Innovation Center, outlines why reshoring API manufacturing requires more than investment incentives.

In today's Pharmaceutical Executive Daily, Invivyd's chief scientific officer discusses a platform designed to predict future viral variants ahead of time, Bristol Myers Squibb expands its AI compute infrastructure with Nvidia to build what it calls the most powerful AI factory in life sciences, and FDA clears Consano Bio's IND for a non-opioid biologic targeting chronic sciatica.

FDA has cleared Consano Bio's IND for C-1101, a platelet-derived biologic delivered via single epidural injection, enabling U.S. expansion of a Phase I trial targeting chronic sciatica.

Bristol Myers Squibb is deploying Nvidia's DGX SuperPOD with Vera Rubin NVL72 systems to build what it claims is the most powerful AI computing infrastructure in life sciences.